NLNK News Alert Newlink Genetics Corp (NLNK) 39.08 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Newlink Genetics Corp (NLNK) 39.08 $NLNK

BARDA awards Ebola vaccine contract to NewLink Genetics
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 7:44AM CST

MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)

NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
GlobeNewswire - Mon Dec 22, 7:00AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)

Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)

NewLink Genetics: Examining Likelihood Of Success In The Impress Trial
Mind Craft - Seeking Alpha - Wed Dec 17, 11:50AM CST
Background The goal of immunotherapy, now recognized as the future direction of cancer treatment [1] , is to boost the immune response, and/or to remove whatever is limiting it, such that the balance shifts from tolerance to rejection. Tumors...
MRK: 57.46 (+0.25), INCY: 71.57 (+1.99), NLNK: 39.08 (+1.36), BMY: 59.15 (-0.01)

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)

Gavi gives Ebola vaccine developers an extra incentive to move quickly
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 10:58AM CST

JNJ: 104.59 (+0.31), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), GSK: 42.85 (+0.11)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 8:11AM CST

SPLS: 17.82 (-0.01), PBR: 7.60 (-0.11), RH: 96.97 (-0.16), PBR.A: 7.95 (-0.04), NLNK: 39.08 (+1.36), LAKE: 8.94 (+0.07), ODP: 8.75 (+0.06), NBG: 1.95 (+0.06)

Merck-NewLink Ebola vaccine trial interrupted
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 7:08AM CST

MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)

Unveiled House Spending Bill Bullish For Ebola Stocks
Matthew Finston - at Seeking Alpha - Wed Dec 10, 8:46AM CST

NVAX: 5.81 (+0.18), NLNK: 39.08 (+1.36), OSUR: 10.26 (+0.25)

Biotech industry group supports adding Ebola to Voucher Program Act
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 12:57PM CST

JNJ: 104.59 (+0.31), BCRX: 11.83 (+0.76), CMRX: 36.80 (+0.70), HEB: 0.22 (-0.02), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), TKMR: 13.97 (+0.14), GSK: 42.85 (+0.11)

Hydration could save many Ebola victims
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:19AM CST

JNJ: 104.59 (+0.31), BCRX: 11.83 (+0.76), HEB: 0.22 (-0.02), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), TKMR: 13.97 (+0.14), GSK: 42.85 (+0.11), IXJ: 100.54 (+0.55), IRY: 47.28 (-0.01)

Phase 1 underway for Ebola booster vaccine regimen
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 7:23AM CST

JNJ: 104.59 (+0.31), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), GSK: 42.85 (+0.11)

Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 6.99 (-0.03), VRTX: 115.15 (+1.40), NLNK: 39.08 (+1.36), IBIO: 0.68 (-0.04), CTIC: 2.36 (+0.05)

Ebola Stocks on the Rise as Death Toll Hits 5,000
ACCESSWIRE - Mon Dec 01, 11:28AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / The death toll from the current Ebola outbreak has nearly hit 5,000 according to the World Health Organization (WHO). While the spread seems to be thankfully slowing, the Ebola stock phenomenon has now transitioned from fear-based speculative buying to concrete capital flows. Lakeland Industries (NASDAQ:LAKE), after surging on the mere news of Ebola and speculation that this would increase demand for the company's hazmat suits, is now surging again on the news that, indeed, the suits are starting to sell. Lakeland last week announced total orders of over one million Ebola suits from both government agencies and private sector customers. Sales will be accretive to earnings after January 31, 2015.
APT: 2.55 (-0.03), NLNK: 39.08 (+1.36), LAKE: 8.94 (+0.07), GSK: 42.85 (+0.11)

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014
M2 - Mon Dec 01, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/22wv9l/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - Adamis - Aeterna Zentaris - Alethia Biotherapeutics - Amgen - AnGes MG - Antoxis - Aphios - Armour - Arno - Astellas Pharma - Astex - AstraZeneca - Ausio - Bavarian Nordic - Bayer - Beta Pharma - Bio-Cancer Treatment International - Biscayne - Boehringer Ingelheim - Celldex - CureTech - CytoVac A/S - DexTech Medical - Enceladus BV - Endo - EndoCeutics - Endocyte - Errant Gene - Fujifilm - Genentech - Glactone Pharma - GlaxoSmithKline - GTx - Harbor - Hybrigenics - Incuron - Io - Isis - Johnson & Johnson - Kinex - Medivation - Medvio Eurasia - Merck KGaA - Millennium - NewLink Genetics - Novartis AG - Oncogenex - Orion Oyj - Orphagen - Oxford BioMedica - Panacela Labs - Tokai - Viamet For more information visit http://www.researchandmarkets.com/research/22wv9l/hormone
JNJ: 104.59 (+0.31), NLNK: 39.08 (+1.36), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)

Dow 30 Stock Roundup: Merck Inks Ebola Deal, UTX CEO Retires - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Nov 28, 11:31AM CST
The Dow has had a largely positive holiday shortened week.
T: 33.96 (-0.07), ERIC: 12.30 (+0.07), IBM: 161.82 (-0.42), UTX: 116.91 (-0.30), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), WMT: 86.43 (-0.23), INTC: 37.44 (+0.01), VZ: 47.67 (unch)

Glaxo's Ebola Candidate Well-Tolerated in Early U.S. Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 10:49AM CST
GlaxoSmithKline's (GSK) Ebola vaccine candidate was well-tolerated in 20 adult volunteers in the U.S.
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), AMAG: 43.02 (+0.90), GSK: 42.85 (+0.11)

InsiderInsights.com Daily Round Up 11/25/14: AAPL, FCF, AVID, SC
InsiderInsights - at Seeking Alpha - Wed Nov 26, 12:20AM CST

SC: 20.09 (-0.19), ACMP: 56.75 (-0.56), NEOT: 6.65 (+0.25), BBY: 38.89 (-0.80), SGM: 12.35 (+0.05), FIVE: 38.76 (-0.11), AVID: 14.36 (+0.26), FCF: 9.21 (-0.04), SPW: 86.64 (-0.11), NLNK: 39.08 (+1.36), AINC: 89.50 (+2.50), PF: 35.32 (+0.13), AAPL: 112.01 (-0.53), SFXE: 4.42 (+0.04), INTU: 94.59 (-0.56), CSCO: 28.30 (+0.05), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 6.61 (+0.06), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), GSK: 42.85 (+0.11), SRNE: 9.50 (+0.99), NEPT: 1.88 (+0.03), CELG: 109.60 (+3.48)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 135

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 53

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 73

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 36

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 246

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Healthcare: ShiftMed Enhances Scheduling at UNC Health

Updated Category News Views 389

Introduction to ShiftMed Flex at UNC Health UNC Health is taking a significant step forward by implementing ShiftMed Flex, a transformative solution aimed at enhancing workforce efficiency throughout its network. This innovative AI-driven platform is designed to improve shift participation by better matching healthcare providers' schedules with available shifts,...

Continue Reading
Rivian's Q4 Financial Performance Sparks Investor Optimism

Updated Category News Views 168

Rivian's Strong Financial Performance Rivian Automotive stock has demonstrated significant resilience and growth recently. Investors are keen to understand the factors that are propelling RIVN stock upward. The latest quarterly earnings report has highlighted Rivian’s remarkable performance, which is robust evidence of the company's progress in the competitive electric...

Continue Reading
Purple Biotech's Innovative Advancements with CAPTN-3 Antibody Platform

Updated Category News Views 295

Exciting Developments in Cancer Treatment from Purple Biotech Purple Biotech, a clinical-stage company at the forefront of oncology, has made impressive strides in its novel tri-specific T cell and NK cell engager platform, known as CAPTN-3. This innovative approach demonstrates sustained tumor regression in an in-vivo model of triple-negative breast cancer and showcases...

Continue Reading
Raytron's Thermal Technology Enhances Robotaxi Safety in All Weather

Updated Category News Views 222

Raytron's Innovative Thermal Cameras for Autonomous Driving As advancements in technology reshape our transportation systems, one major player in the field is Raytron, a leader in infrared thermal imaging. A pressing challenge in the rollout of Level 4 (L4) robotaxis is ensuring safe operation in various climatic conditions, especially during extreme weather. With...

Continue Reading
Investors Urged to Join Centene Corporation Class Action Now

Updated Category News Views 116

Centene Corporation Faces Class Action Lawsuit Levi & Korsinsky, LLP has officially notified investors about a class action lawsuit targeting Centene Corporation. This lawsuit may affect shareholders who experienced losses due to alleged securities fraud. Centene Corporation, identified by its ticker CNC, is at the center of this legal action, which has drawn attention...

Continue Reading